6IB Stock Overview
A biopharmaceutical company, develops, manufactures and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Innovent Biologics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$6.00 |
| 52 Week High | HK$6.30 |
| 52 Week Low | HK$3.64 |
| Beta | 0.28 |
| 1 Month Change | 14.29% |
| 3 Month Change | 31.00% |
| 1 Year Change | 28.21% |
| 3 Year Change | 134.38% |
| 5 Year Change | 20.00% |
| Change since IPO | 200.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6IB | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 8.1% | -1.6% | 0.8% |
| 1Y | 28.2% | -13.5% | 15.0% |
Return vs Industry: 6IB exceeded the German Biotechs industry which returned -12.7% over the past year.
Return vs Market: 6IB exceeded the German Market which returned 14.4% over the past year.
Price Volatility
| 6IB volatility | |
|---|---|
| 6IB Average Weekly Movement | 11.9% |
| Biotechs Industry Average Movement | 5.8% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in DE Market | 12.8% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 6IB's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 6IB's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 5,659 | Michael Yu | www.innoventbio.com |
Innovent Biologics, Inc., a biopharmaceutical company, develops, manufactures and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retevmo, a selective and potent RET kinase inhibitor. The company is also developing Fucaso, a fully human (BCMA)-directed CAR-T cell; Dupert, a novel KRAS G12C inhibitor; DOVBLERON, a novel next-generation ROS1 TKI in-licensed ; Jaypirca, a non-covalent (reversible) BTK inhibitor; SYCUME, a recombinant IGF-1R monoclonal antibody; IBI354, a recombinant anti-HER2 ADC; IBI389, a first-in-class CLDN18.2/CD3 bispecific T cell engager; IBI3009,a potential best-in-class DLL3-targeting ADC; IBI3001, a potentially bispecific ADC against B7-H3 and EGFR; IBI3020,potential dual payload ADC targeting CEACAM5; IBI356,a potential anti-OX40L monoclonal antibody; IBI355,a potential anti-CD40L monoclonal antibody; IBI3002, a first-in-class TSLP/IL-4a bispecific antibod; IBI3016,a siRNA drug candidate targeting AGT; collaborated with SanegeneBio;and IBI112, a novel long-acting anti-IL-23.
Innovent Biologics, Inc. Fundamentals Summary
| 6IB fundamental statistics | |
|---|---|
| Market cap | €9.95b |
| Earnings (TTM) | -€11.67m |
| Revenue (TTM) | €1.16b |
Is 6IB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6IB income statement (TTM) | |
|---|---|
| Revenue | CN¥9.42b |
| Cost of Revenue | CN¥2.41b |
| Gross Profit | CN¥7.01b |
| Other Expenses | CN¥7.10b |
| Earnings | -CN¥94.63m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.057 |
| Gross Margin | 74.40% |
| Net Profit Margin | -1.00% |
| Debt/Equity Ratio | 21.5% |
How did 6IB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 17:58 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Innovent Biologics, Inc. is covered by 57 analysts. 28 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Bo Li | BofA Global Research |
| Shun Kei Law | CCB International Securities Limited |
| Zhishun Siu | CCB International Securities Limited |